Related by context. All words. (Click for frequent words.) 71 dose limiting toxicities 69 pharmacokinetics PK 69 Maximum Tolerated Dose MTD 68 dose escalation trial 68 limiting toxicity 68 Phase 1b trial 68 safety tolerability pharmacokinetics 67 optimal dosing 67 pharmacokinetic profile 67 safety tolerability pharmacokinetic 67 phase Ib 66 Phase Ib II 66 ascending dose 66 maximally tolerated dose 66 tolerability 65 Bezielle 65 Phase 1b 65 dose cohorts 65 Phase Ib 65 blinded randomized placebo controlled 65 bevirimat Study 65 dose escalation 65 nab paclitaxel 64 INCB# [001] 64 alvespimycin 64 pharmacodynamic PD 64 dose escalation study 64 pharmacodynamic effects 64 CR# vcMMAE 64 limiting toxicity DLT 64 Tarceva TM 64 dosing cohort 64 DLTs 64 pharmacodynamic profile 64 oral ridaforolimus 64 Elesclomol 64 Azedra 64 HGS ETR1 64 antitumor activity 64 pharmacodynamics PD 64 Panzem R NCD 64 IMGN# 64 safety tolerability 64 dosage regimens 64 Dose escalation 64 #mg/m# [002] 63 Phase Ib study 63 MAGE A3 ASCI 63 PRTX 63 dose cohort 63 pharmacokinetics 63 pertuzumab 63 PEG SN# 63 phase IIb clinical 63 Phase Ib clinical 63 GAMMAGARD 63 Cloretazine R VNP#M 63 pharmacokinetic PK 63 label dose escalation 63 tolerability pharmacokinetics 63 relapsed MM 63 dose regimens 63 PEG Interferon lambda 63 neratinib 63 mertansine 63 favorable pharmacokinetic profile 63 Phase #b/#a clinical 63 velafermin belinostat 63 phase IIb 62 orally bioavailable 62 analgesic efficacy 62 safety tolerability pharmacodynamics 62 Phase 2a trial 62 Phase IIIb clinical 62 teriflunomide 62 phase IIb study 62 Phase 2b study 62 BRIM2 62 PSMA ADC 62 preclinically 62 RG# ITMN 62 dose escalation phase 62 anti leukemic 62 ascending doses 62 Pralatrexate 62 oral prodrug 62 antiviral efficacy 62 PREZISTA r 62 forodesine 62 thymalfasin 62 registrational 62 maximal tolerated 62 prospectively defined 62 huC# DM4 62 PEGylated interferon beta 1a 62 IMC A# 62 Archexin 62 Phase Ib clinical trials 62 huN# DM1 62 investigational oral 62 mcg kg 62 SCH # 61 AQ4N 61 pharmacokinetic parameters 61 plasma pharmacokinetics 61 Traficet EN 61 noninferiority 61 mg/m2/day 61 confirmatory clinical 61 optimal dosing regimens 61 elotuzumab 61 ELND# 61 Maximum Tolerated Dose 61 Forodesine HCl 61 Tanespimycin 61 #D#C# 61 ganetespib 61 lesinurad 61 oral deforolimus 61 ARIKACE 61 Phase #/#a 61 efficacy tolerability 61 HCD# [002] 61 pharmacodynamic 61 Pharmacokinetics PK 61 phase IIb trial 61 MAP# 61 YONDELIS 61 Phase IIa trial 61 orally administered inhibitor 61 selective modulator 61 azacitidine 61 CIMZIA TM 61 OMP #M# 61 Phase 1a 61 CEQ# 61 Pegasys ® 61 DermaVir Patch 61 TACI Ig 61 double blinded placebo 61 lomitapide 61 Tyrima 61 galiximab 61 Phase 1b clinical 61 melphalan prednisone 61 secondary efficacy endpoint 61 Primary endpoints 61 dose escalation Phase 61 Multimeric 61 NATRECOR ® 61 intermittent dosing 61 evaluable subjects 61 nucleoside reverse transcriptase inhibitor 61 pharmacodynamics 61 tanespimycin 61 lorvotuzumab mertansine 61 polymerase inhibitor 61 torezolid phosphate 60 Teriflunomide 60 phase IIa 60 mg/m2 60 HGS# 60 systemically administered 60 AAG geldanamycin analog 60 imetelstat 60 Poly ICLC 60 heavily pretreated 60 AEG# 60 phase IIa clinical 60 PXD# 60 antibody MAb 60 CCX# 60 Cloretazine 60 non nucleoside 60 lead Aganocide compound 60 IIa trial 60 pharmacokinetic PK study 60 receptor tyrosine kinase inhibitor 60 viral kinetics 60 Phase 2b trial 60 ORMD 60 ZOLINZA 60 treatment naive genotype 60 liposomal formulation 60 administered subcutaneously 60 efficacy endpoint 60 dosing regimens 60 Allovectin 7 ® 60 Ceplene/IL-2 60 Sym# 60 Ophena TM 60 CLORETAZINE TM VNP#M 60 pharmacokinetic PK profile 60 paclitaxel poliglumex 60 aplindore 60 multicenter Phase 60 indibulin 60 Phase Ia 60 multiple ascending dose 60 novel VDA molecule 60 Omacetaxine 60 Omacetaxine mepesuccinate 60 rNAPc2 60 CD4 monoclonal antibody 60 eniluracil 60 varespladib 60 TMC# C# 60 nonclinical studies 60 APTIVUS r 60 APTIVUS 60 ISTODAX 60 Chemophase 60 relapsed refractory multiple myeloma 60 Enzastaurin 60 viral kinetic 60 cilengitide 60 tolerability profile 60 #mg/m# [001] 60 blinded placebo controlled 60 randomized Phase III 60 single ascending dose 60 ELACYT 60 Sapacitabine 60 mg/m2 dose 60 R#/MEM # 60 unique alkylating agent 60 CIMZIA ™ 60 multicenter randomized placebo controlled 60 investigational protease inhibitor 60 GMX# 60 ritonavir boosted 60 KRN# 60 FOLOTYN ® 59 antitumor effect 59 Octreolin 59 mg/m2 administered 59 nucleoside analog 59 ZACTIMA 59 investigational humanized monoclonal antibody 59 Aflibercept 59 fosbretabulin 59 XL# XL# XL# XL# 59 edoxaban 59 MEND CABG II 59 dosing cohorts 59 GSK# [001] 59 Arikace 59 lintuzumab SGN 59 placebo controlled clinical 59 OvaRex R 59 controlled multicenter 59 oral rivaroxaban 59 dexpramipexole 59 pharmacodynamic properties 59 Blinatumomab 59 MORAb 59 PRIMO CABG2 59 ongoing Phase 1b 59 HGS ETR2 59 HER2 positive metastatic breast 59 randomized multicenter trial 59 active comparator 59 HuMax EGFr 59 rALLy trial 59 AEGR 59 estramustine 59 erlotinib Tarceva ® 59 hA# 59 telaprevir dosed 59 SAR# [004] 59 refractory NSCLC 59 DP b# 59 masked placebo controlled 59 inhibitor RG# 59 evaluating tivozanib 59 deforolimus 59 subcutaneously administered 59 JAK2 inhibitor 59 immunomodulator 59 rALLy clinical trial 59 humanized monoclonal antibody 59 urate lowering 59 docetaxel Taxotere R 59 secondary efficacy endpoints 59 Aurexis 59 PNP inhibitor 59 lintuzumab 59 MGd 59 pharmacokinetics pharmacodynamics 59 JAK inhibitor 59 dacetuzumab 59 novel histone deacetylase 59 gemcitabine Gemzar ® 59 TG# [003] 59 docetaxel Taxotere ® 59 GFT# 59 riociguat 59 plus Copegus R 59 Seliciclib 59 docetaxel chemotherapy 59 budesonide foam 59 Virulizin ® 59 IV bolus 59 mcg dose 59 EDEMA3 59 Dose Limiting Toxicity DLT 59 Zerenex 59 BAY #-# 59 samalizumab 59 Phase IIb clinical trials 59 plus prednisone prednisolone 59 sunitinib malate 59 randomized discontinuation trial 59 Xanafide 59 investigational monoclonal antibody 59 MEK Inhibitor 59 ancrod 59 Phase IIb trials 59 BENICAR HCT 59 PRT# 59 CoFactor 59 Asentar 59 mGluR5 NAM 59 Neuradiab 58 Multiple Ascending Dose 58 LUX Lung 58 posaconazole 58 GLYX 58 multicenter Phase II 58 efficacy 58 mg dose 58 LibiGel Phase III 58 Aclidinium 58 CTAP# Capsules 58 metastatic hormone refractory 58 metastatic castration resistant 58 leading oral taxane 58 PSN# [002] 58 ACTEMRA TM 58 class mGluR5 inhibitor 58 ENMD # 58 RE LY ® 58 pharmacokinetic characteristics 58 vicriviroc 58 tezampanel 58 Elotuzumab 58 Exelixis compounds 58 EMPHASIS HF trial 58 urocortin 2 58 ToGA 58 abacavir lamivudine 58 Lenocta 58 Cloretazine ® 58 Anturol TM 58 HuLuc# 58 BRIM3 58 refractory chronic lymphocytic 58 FOLOTYN 58 NOX E# 58 trastuzumab Herceptin R 58 AZD# 58 temsirolimus 58 registrational trial 58 CRMD# 58 AZILECT R 58 imatinib therapy 58 serum concentrations 58 tecarfarin 58 tezampanel NGX# 58 PF # [001] 58 μg dose 58 IMiDs ® 58 Azixa 58 peginesatide 58 multicentre randomized 58 trial evaluating PRX# 58 Phase IIa trials 58 PEGylated Fab fragment 58 adecatumumab 58 rapid virologic response 58 Imprime PGG 58 generation purine nucleoside 58 PDE4 inhibitor 58 CCR5 antagonist 58 bicifadine 58 composite endpoint 58 AVE# 58 Serdaxin 58 CG# [003] 58 intravenously administered 58 humanized anti 58 intravitreal insert 58 PROMACTA 58 INCB# [003] 58 Pemetrexed 58 EGFR TKI 58 TAXUS VI 58 bendamustine 58 XmAb# 58 dose dexamethasone 58 evaluating Actimmune 58 Cotara 58 prospective randomized placebo 58 Vicinium TM 58 relapsed myeloma 58 NGX# 58 placebo controlled Phase 58 mapatumumab 58 Phase #b/#a 58 STRIDE PD 58 NP2 Enkephalin 58 Proellex TM 58 investigational compound 58 prodrug 58 MGCD# [002] 58 vorinostat 58 Phase 2a clinical 58 monoclonal antibody conjugated 58 Phase IIB 58 Cmax 58 nucleoside naive patients 58 HCV replicon 58 Bicifadine 58 GAP #B# 58 vidofludimus 58 eltrombopag 58 plasma kallikrein inhibitor 58 placebo controlled Phase III 58 Androxal TM 58 Prostate AdenoCarcinoma Treatment 58 APOPTONE 58 R baclofen 58 obatoclax 58 antiviral activity 58 epoetin alpha 58 trastuzumab DM1 58 REG2 58 Adalimumab 58 Belimumab 58 Laquinimod 58 immunogenicity 58 #mg QD [002] 58 Elvitegravir 58 Allovectin 7 R 58 hyperphenylalaninemia HPA due 58 GRN#L 58 ANCHOR trial 58 Cethromycin 58 bevacizumab Avastin ® 58 Perifosine 58 MIRCERA 58 transcriptase inhibitor NNRTI 58 creatinine clearance CrCl 58 AKT inhibitor 58 certolizumab 58 Melphalan 58 solithromycin 58 oral methylnaltrexone 58 GLPG# 58 preclinical efficacy 58 ularitide 58 compound INCB# 57 talactoferrin 57 8mg/kg 57 phase IIIb 57 mg BID 57 CYT# QbG# 57 protease inhibitor PI 57 Phase IIa clinical 57 TMC# [002] 57 dosed orally 57 Zenvia ™ 57 pomalidomide 57 Vidofludimus 57 dasatinib Sprycel ® 57 bortezomib Velcade R 57 GLP toxicology studies 57 plasma concentrations 57 albiglutide 57 randomized Phase 2b 57 AP# [003] 57 #I TM# 57 custirsen 57 PRE SURGE 57 ofatumumab 57 trastuzumab emtansine T DM1 57 ataluren 57 angiogenesis inhibitor 57 RG# [001] 57 refractory CLL 57 Phase 1a clinical 57 targeted radiotherapeutic 57 Non inferiority 57 Carfilzomib 57 REVLIMID lenalidomide 57 Phase 1b dose escalation 57 weekly subcutaneous injections 57 Amplimexon 57 GW# [003] 57 Randomized Double blind 57 Actilon 57 Vandetanib 57 pharmacodynamic markers 57 HQK 57 thorough QT 57 amprenavir 57 Phase #b/#a trial 57 randomized controlled Phase 57 subcutaneous dose 57 drug pipeline TAFA# 57 OHR/AVR# 57 depsipeptide 57 velafermin 57 eritoran 57 ixabepilone 57 dose dose escalation 57 alfa 2a 57 ThermoDox R 57 ospemifene 57 mg kg BID 57 beta2 agonist 57 vandetanib 57 pharmacokinetic 57 ZD# [001] 57 pharmacodynamic profiles 57 CANCIDAS 57 lenalidomide Revlimid R 57 Solazed 57 neurologic progression 57 TOLAMBA 57 #mg dose [002] 57 potent triglyceride lowering 57 NVA# 57 glufosfamide 57 Phase 2a 57 BAL# [002] 57 vemurafenib 57 controlled multicenter Phase 57 APRISO 57 VELCADE melphalan 57 Trofex 57 Phase IIb clinical 57 recurrent glioblastoma multiforme 57 Fibrillex TM 57 Prospective Randomized 57 axitinib 57 Hsp# Inhibitor 57 doxorubicin docetaxel 57 cleavable linker 57 achieved statistical significance 57 RiVax 57 motesanib 57 oral antiviral 57 Phase 2b Clinical Trial 57 #mg dose [001] 57 refractory AML 57 prucalopride 57 Dose Escalation 57 HuMax CD4 57 RE LY 57 bile duct tumor 57 dose proportionality 57 CTA# Injection 57 rHuPH# 57 Welchol 57 mg TID 57 EGFR HER2 57 hemagglutination inhibition HAI 57 Response Evaluation Criteria 57 Darusentan 57 pharmacokinetic interactions 57 primary hypercholesterolemia 57 Dapagliflozin 57 non nucleoside HCV 57 Aztreonam lysine 57 Medidur TM FA 57 R# #mg BID 57 Panzem R 57 rFIXFc 57 Bortezomib 57 Phase 1b clinical trials 57 TNF Tumor Necrosis Factor 57 RhuDex ® 57 dosage regimen 57 TKM ApoB 57 phase 2a 57 HES CEL 57 MGCD# [001] 57 DU #b 57 ARIKACE ™ 57 Anthim 57 ara C 57 ZK EPO 57 Initiate Phase 57 Solid Tumors criteria 57 QD dosing 57 sorafenib Nexavar ® 57 Pharmacokinetic 57 Elagolix 57 bronchodilation 57 sapacitabine 57 Golimumab 57 Cariprazine 57 corticosteroid dose 57 efficacy endpoints 57 LEXIVA r 57 EOquin TM phase 57 placebo controlled 57 ULORIC 57 CBLC# 57 relapsed MCL 57 diabetic neuropathic pain 57 nalbuphine ER 57 DAVANAT 57 PTH analogue 57 Empatic 57 celgosivir 57 Meets Primary Endpoint 57 TG# [001] 57 ruxolitinib 57 visilizumab 57 ascending dose study 57 tubulin inhibitor 57 PRADAXA 57 Posiphen 57 insulin degludec 57 Vitaxin 57 Exelixis XL# 57 Phase IIa 57 subcutaneous PRO 57 LIALDA 57 multi kinase inhibitor 57 AzaSite Plus 57 placebo controlled clinical trials 57 azilsartan medoxomil 57 Darunavir 57 Triolex 57 PROPEL trial 57 non inferiority 57 pharmacokinetic pharmacodynamic 57 elacytarabine 57 VEGFR2 inhibitor 57 sorafenib tablets 57 pralatrexate 57 BENICAR 57 ulimorelin 57 Lucanix R 57 endoscopic gastric ulcers 57 concentration Cmax 57 NO# [002] 57 Plicera 57 EFAPROXYN 56 CML CP 56 KNS # 56 Voreloxin 56 EDEMA3 trial 56 LY# [003] 56 neuroprotective properties 56 ritonavir boosted danoprevir 56 ADVANCE PD 56 placebo controlled randomized 56 HCV SPRINT 56 hour bronchodilation 56 paclitaxel Taxol ® 56 Vidaza azacitidine 56 selective androgen receptor modulator 56 JANUVIA 56 serum phosphorus 56 Prodarsan ® 56 CYT# potent vascular disrupting 56 peg interferon 56 IMA# 56 Triapine R 56 pegylated interferon alfa 2a 56 ATL# [001] 56 anticancer activity 56 cangrelor 56 KSP inhibitor 56 romidepsin 56 Phase #/#a trial 56 randomized multicenter 56 IL# PE#QQR 56 MabCampath 56 PI3K/Akt pathway inhibitor 56 PegIFN RBV 56 trabedersen 56 mg QD 56 Hematologic toxicity 56 TBC# 56 taxane resistant 56 Brentuximab vedotin 56 tipranavir 56 confirmatory Phase III 56 mg/m2 cohort 56 Dasatinib 56 bortezomib Velcade 56 multicenter Phase III 56 dacarbazine 56 subcutaneous SC 56 adecatumumab MT# 56 MEK inhibitor 56 Ostarine 56 sorafenib Nexavar 56 CDK inhibitor 56 eribulin mesylate 56 Abiraterone acetate 56 Genasense ® oblimersen 56 SIMPADICO 56 neoadjuvant 56 JVRS 56 Epratuzumab 56 RE SURGE 56 ThermoDox ® clinical 56 ThermoDox ® 56 CA4P 56 OMNARIS HFA 56 dose escalation clinical 56 low dose cytarabine 56 lanthanum carbonate 56 KOMBIGLYZE XR 56 eculizumab 56 mg m² 56 By JENNIFER LEARN 56 Phase III HEAT 56 enzastaurin 56 dosing interval 56 IIa clinical 56 decitabine 56 PDX pralatrexate 56 MGN# 56 favorable tolerability 56 Valortim 56 Clonicel 56 Tolerability 56 #mg BID [003] 56 tipranavir r 56 pain palliation 56 BrachySil TM 56 Antiviral Activity 56 LHRH antagonists 56 orally dosed 56 baminercept 56 TKB# 56 relapsed multiple myeloma 56 ketolide antibiotic 56 Anticalins 56 COPEGUS 56 RSD# oral 56 subcutaneous doses 56 systemic RNAi therapeutic 56 rindopepimut 56 Zoraxel 56 FOLFOX6 chemotherapy regimen 56 Phase III confirmatory 56 oral FTY# 56 injectable investigational 56 otelixizumab 56 Altastaph 56 CHAMPION PCI 56 MDV# 56 mCi kg 56 Methylnaltrexone 56 oral isoform selective HDAC 56 HDAC Inhibitor 56 double blinded randomized 56 Amrubicin 56 castrate resistant prostate cancer 56 adjuvant GIST 56 Talabostat 56 confirmatory Phase 3 56 pharmacokinetic equivalence 56 optimal dosing regimen 56 PEG PAL 56 NeuroSTAT ® 56 gemcitabine cisplatin 56 hypoxia activated prodrug 56 Phase IIb 56 Nanobody 56 adalimumab 56 LUVENIQ 56 mocetinostat 56 Tumor Response 56 Pharmacokinetic parameters 56 acyclovir Lauriad R 56 non nucleoside inhibitor 56 TYKERB 56 ONCONASE 56 CCR5 mAb 56 Afatinib 56 peritumoral brain edema 56 Eltrombopag 56 teduglutide 56 SYMMETRY trial 56 administered orally 56 interferon alfa 56 superficial bladder cancer 56 BCIRG 56 Phase 2b clinical trials 56 Zemplar Capsules 56 Annamycin 56 nanopharmaceutical 56 Aurora kinase inhibitor 56 Kahalalide F 56 satraplatin Phase 56 Durezol 56 Kinoid 56 Ofatumumab 56 OMP #R# 56 Quinamed 56 ALN TTR 56 mg administered orally 56 erythropoietic 56 registrational Phase 56 desvenlafaxine succinate 56 interferon gamma 1b 56 EDEMA4 trial 56 MP4OX 56 evaluating Xcytrin 56 serum phosphate 56 HGS ETR1 mapatumumab 56 incyclinide 56 Neurodex 56 highly immunogenic 56 intradermal injections 56 apricitabine 56 mg qd 56 GSK # 56 Allovectin 7 56 clevidipine 56 Mipomersen 56 Phase III randomized controlled 56 aliskiren 56 piperacillin tazobactam 56 Viprinex 56 HBeAg negative 56 iobenguane 56 cell lymphoma CTCL 56 intranasal formulation 56 CRLX# 56 MTP inhibitor 56 alicaforsen enema 56 BEXXAR 56 mg kg dose 56 Omnitarg 56 RH1 56 delafloxacin 56 randomized blinded 56 systemic immunosuppressive drugs 56 Androxal ® 56 investigational pan BCR 56 immunosuppressive compound 56 initiate Phase 1b 56 MoxDuo TM IR 56 seroprotection 56 cancer neuroendocrine tumor 56 RANK Ligand inhibitor 56 StemEx 56 ALVESCO 56 TYGACIL 56 monotherapy 56 metastatic castrate resistant 56 DORIBAX 56 ENRICH trial 56 nucleotide analog 56 Q#IR 56 aflibercept 56 multicenter randomized 56 randomized multicenter Phase III 56 Safinamide 56 GATTEX ® 56 placebo controlled dose escalation 56 IMC #B 56 HCV protease 56 eliglustat tartrate 56 CD# monoclonal antibody 56 dosing schedules 56 Onrigin 56 IMiDs ® compound 56 ofatumumab HuMax CD# 56 recombinant PSMA vaccine 55 fluvastatin 55 valopicitabine 55 interferon beta therapy 55 ADAGIO study 55 relapsing multiple sclerosis 55 primary efficacy endpoint 55 treatment naïve genotype 55 virus HCV protease inhibitor 55 Dextofisopam 55 nucleoside naive 55 INSPIRE Trial Phase III 55 GOUT 55 OncoVEX GM CSF 55 vascular disrupting agent 55 atrasentan 55 ZYBRESTAT 55 albinterferon alfa 2b 55 Aplidin R 55 ispinesib 55 eprotirome 55 T DM1 55 PEGylated anti 55 3 registrational trial 55 serum phosphorous 55 RECIST Response Evaluation Criteria 55 INC# 55 AIR CF1 55 dependent kinase inhibitor 55 AVONEX ® 55 intravesical infusion therapy 55 LB# [003] 55 hENT1 55 PANVAC VF 55 VITAL Trial 55 pegylated interferon alpha 55 Phase 2b clinical 55 SUCCEED trial 55 cannabinor 55 NPC 1C 55 mg m 55 FOLPI regimen 55 includes TOLAMBA TM 55 EURIDIS 55 Aplidin 55 SILENOR 55 evaluable 55 plus COPEGUS 55 DOXIL 55 CYC# 55 RGB # 55 NATRECOR R 55 mg BID dose 55 demonstrated antitumor activity 55 Rigel R# 55 randomized Phase 55 Stedivaze 55 Ceflatonin 55 IRX 2 55 NSABP B 55 CYT# 55 venlafaxine XR 55 ABSORB trial 55 Ocrelizumab 55 genotypic resistance 55 standard chemotherapy regimen 55 K ras mutations 55 dirucotide MBP# 55 cariprazine 55 XL# anticancer compounds 55 VAPRISOL 55 Board DSMB 55 Phase Ib IIa 55 Pharmacokinetic studies 55 Pharmacokinetic PK 55 RECIST criteria 55 anti EGFR antibody 55 SPRIX ® 55 atherothrombotic events 55 ILLUMINATE 55 BLA submission 55 lucinactant 55 prostate cancer AIPC 55 regorafenib 55 Acute Ischemic Stroke 55 blind randomized placebo 55 undetectable HBV DNA 55 FOLPI 55 bortezomib 55 subcutaneous formulation 55 octreotide implant 55 ertapenem 55 maximal dose 55 dirucotide 55 sapacitabine CYC# 55 histone deacetylase HDAC inhibitor 55 KB# [002] 55 Revimmune 55 Glufosfamide 55 ROCKET AF 55 anti amnesic 55 REOLYSIN ® 55 telaprevir VX 55 PegIFN 55 HepeX B TM 55 irbesartan 55 NEUMUNE 55 dose titration 55 2 methoxyestradiol 55 PEARL SC 55 RELOVAIR ™ 55 KRAS status 55 LEVADEX 55 DCCR 55 Phase III Clinical Trial 55 Pafuramidine 55 Romidepsin 55 bavituximab 55 mg q#h 55 PLK1 SNALP